We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Rapid Method Detects Urinary Tract Infections

By LabMedica International staff writers
Posted on 22 May 2012
The reliability of a rapid detection method for urinary tract infection (UTI) has been compared with the reference standard streaked agar plate method. More...


The novel CultureStat Rapid UTI Detection System (CSRUDS) consists of a vacuum-sealed glass ampoule containing trypticase soy broth dry media and triphenyl tetrazolium chloride, a chromophore indicator sensitive to dehydrogenase.

Scientists at Columbia University Medical Center, (New York, NY, USA) working with others, selected 980 clean catch urine samples into specimen cups during a 30-day period. Each specimen was streaked on separate 5% sheep blood agar plates and simultaneously a 7-mL aliquot of each fresh urine specimen was processed using the CSRUDS. A spectrophotometer linked to a computer and a bar code scanner was used to identify and test each urine sample.

Positive UTI conditions were accurately identified by both CSRUDS and agar streak plate methods. CSRUDS accurately identified UTI negative conditions with 99.3% reliability at 90 minutes. The negative predictive value of CSRUDS was 99.2% at 30 minutes. The bacterial plating results revealed that 413 (58.8%) of the CSRUDS negative group demonstrated no bacterial growth at all, and 289 (41.2%) of the CSRUDS negative group showed some degree of bacterial growth. Of the 289 samples, 82 (28.4%, including one of the six CSRUDS false-negative samples), showed bacterial growth in the 50,000 colony forming units (CFU) range and 200/289 (69.2%), including the other five false-negative CSRUDS samples, had CFU counts of 1,000-49,000 CFUs or mixed flora. Of the 289, 7 (2.4%) had growth greater than 100,000 colonies/mL.

The author concluded that he novel rapid detection system evaluated in this test program, the CSRUDS and MB80CSENC spectrophotometer (MicroBionetics, Eldersburg, MD, USA) provided UTI negative/positive same-day results within 90 minutes from the start of the test, with a highly reliable negative predictive value within 30 minutes for most patients. Because it is such a rapid test, contamination at urine collection is unlikely to affect the results of the assay. Specimen transport and delays in processing the urine sample are obviated because the test can be immediately performed in the urologist's office where the specimen was collected. The study was published in the April 2012 issue of the journal Urology.

Related Links:
Columbia University Medical Center
MicroBionetics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.